Limited efficacy of 3 + 7 plus gemtuzumab ozogamycin in newly diagnosed fit intermediate genetic risk acute myeloid leukemia patients.
Bianca SerioFrancesco GrimaldiLucia AmmiratiMario AnnunziataGiovanna De SantisAlessandra PerrottaDanilo De NovellisValentina GiudiceDenise MoriniGabriella StortiCatello CalifanoAntonio Maria RisitanoFabrizio PaneCarmine SelleriPublished in: Cancer reports (Hoboken, N.J.) (2024)
Our real-life multicenter study confirmed GO-based treatment efficacy with high MRD negativity rates in fit newly diagnosed AML patients, especially in those with low genetic risk and core binding factor, while limited benefits were observed in intermediate-risk AML. However, further validation on larger prospective cohorts is required.
Keyphrases
- newly diagnosed
- acute myeloid leukemia
- end stage renal disease
- ejection fraction
- chronic kidney disease
- prognostic factors
- allogeneic hematopoietic stem cell transplantation
- peritoneal dialysis
- genome wide
- gene expression
- patient reported outcomes
- acute lymphoblastic leukemia
- copy number
- dna methylation
- clinical evaluation